TAK-994 is an oral, selective OX2R agonist?developed by Takeda for the treatment of narcolepsy type 1 (with?cataplexy) and type 2 (without cataplexy). The molecule follows Takedas previous clinical molecule,?TAK-925?(danavorexton), which was the first O
CAS Nummer:
[2861934-86-1]
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten